Pulmonary sarcoidosis: infliximab – evidence summary (ES2)

Summary found evidence supports guidance from the British Thoracic Society that immunosuppressants (e.g. infliximab) have a limited role in pulmonary sarcoidosis as there are insufficient high-quality studies to confirm place in therapy and they have significant adverse effects.

The guidance advises that immunosuppressants should be used only when disease is refractory to standard treatments and when there are no pharmacological alternatives.